Mural Oncology Presents Preclinical Data For IL-18 and IL-12 Programs At 2024 American Association For Cancer Research Annual Meeting

For the first time, the company shares data for its preclinical IL-18 and IL-12 programs—candidate nominations for each are expected later this year

 

Combination of IL-18 binding protein resistance with additional half-life enhancement to IL-18 variant demonstrated durable immunological effects in preclinical models

Data presented suggest dual-targeted, subunit approach to engineered IL-12 may mitigate cytokine's hallmark toxicity without compromising efficacy